2016 was a lousy year for biotech investors but TheStreet.com's Adam Feuerstein's biotech tweets were on point! It started when his beloved dog died right after New Year's Day and then MannKind (MNKD) went KABOOM! Another bad omen for 2016: A news-free start to the J.P. Morgan Healthcare conference, followed fast by the FDA's decision to postpone the Sarepta (SRPT) advisory panel. The year started bad and never really stopped being bad. Let's hope 2017 is better than 2016 and the tweets keep coming @AdamFeuerstein
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.